- | Cue Biopharma
Company Spotlight: Cue Biopharma Innovates in the Immunotherapy Space with its Immuno-STAT Platform
Immunotherapy continues to be a burgeoning field, with immune-based therapies being among the leading treatments being developed in oncology and autoimmunity.
- | Immunomedics
Promise of ADCs in solid tumours: Immunomedics partners with Roche
Roche and Immunomedics have expanded their checkpoint inhibitor-ADC partnership from TNBC to include other solid tumours: UC and NSCLC. What promise does combining ADC Trodelvy and checkpoint inhibitor Tecentriq have in overcoming unmet needs in these cancer types?
- | Anima Biotech
Targeting “Undruggable” Proteins by Selectively Controlling mRNA Translation
Many human diseases are driven by the dysfunction or dysregulation of proteins. However, up to 80% of proteins do not possess binding sites suitable for direct binding of small molecule drugs, making them “undruggable”. To overcome this problem, Anima Biotech has developed their Translation Control Therapeutics platform to identify drugs with the ability to interfere with the production of these “undruggable” proteins, by selectively inhibiting the translation of mRNA.
- | Ziopharm Oncology
Phase 2 Trial Using IL-12 Gene Therapy for Glioblastoma Reaches Recruitment Target
A novel immune-based, gene therapy approach is entering phase 2 trials (ClinicalTrials.gov Identifier: NCT04006119) for glioblastoma multiforme (GBM) after promising preliminary safety and efficacy data. Despite encouraging results in several tumor types such as melanoma, colorectal, and lung, immunotherapies have yet to show any significant benefit in patients with brain tumors. The new technique by Ziopharm hopes to reverse that trend.
- | Arrowhead Pharmaceuticals
First Participants Dosed in Early Clinical Trial of Inhaled Therapy ARO-ENaC
A Phase 1/2 clinical trial assessing Arrowhead Pharmaceuticals‘ investigational inhaled therapy, ARO-ENaC, for the treatment of cystic fibrosis (CF), has dosed its first participants, the company announced.
- | Ansun Biopharma
Russia approves coronavirus vaccine but international community is skeptical
FOX Business’ Ashley Webster on how the international community is reacting to Russia’s announcement of a coronavirus vaccine.
- | Arrowhead Pharmaceuticals
Arrowhead Pharma Pres. & CEO Dr. Christopher Anzalone On Taking RNA Interference Beyond The Liver
Arrowhead Pharmaceuticals leader Christopher Anzalone, Ph.D. gives us the inside story on the stake his company claimed on the now re-burgeoning RNAi space, the indications his company is targeting beyond liver disease, and how it’s addressing the development and process challenges that must be overcome to further progress RNAi beyond the liver.
- | GigaGen
GigaGen Publishes Data on New Recombinant Hyperimmune Drug Class as COVID-19 Therapy
Convalescent therapy has been touted as a fast, effective response to COVID-19, but a new therapy by GigaGen Inc. could be even more promising. GIGA-2050, a new class of drug called a recombinant hyperimmune, offers 100-fold higher potency than convalescent serum therapy.
